Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
Investing in Malaysia's largest clinic operator to expand the healthcare business
Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Subscribe To Our Newsletter & Stay Updated
